ICU Medical Announces Third Quarter 2026 Results
and Reaffirms Fiscal Year 2026 Guidance, Expecting Results at the High End of Range SAN CLEMENTE, Calif., November 5, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended September 30, 2026.
Third quarter 2026 GAAP revenue was $560.4 million, as compared to $537.0 million in the same period in the prior year. GAAP gross profit for the third quarter of 2026 was $234.8 million, as compared to $200.9 million in the same period in the prior year. GAAP gross margin for the third quarter of 2026 was 42%, as compared to 37% in the same period in the prior year. GAAP net income for the third quarter of 2026 was $26.8 million, or $1.07 per diluted share, as compared to GAAP net loss of $(3.4) million, or $(0.14) per diluted share, for the third quarter of 2025. Adjusted diluted earnings per share for the third quarter of 2026 was $2.44 as compared to $2.03 for the third quarter of 2025. Adjusted EBITDA was $113.9 million for the third quarter of 2026 as compared to $105.9 million for the third quarter of 2025.
Adjusted EBITDA and adjusted diluted earnings per share are measures calculated and presented on the basis of methodologies other than in accordance with GAAP. Please refer to the Use of Non-GAAP Financial Information following the financial statements herein for further discussion and reconciliations of these measures to GAAP measures.
Vivek Jain, ICU Medical’s Chief Executive Officer, said, “Third quarter results were ahead of our expectations for Infusion Systems and generally in line with expectations for the remainder of the business."
Revenues by product line for the three and nine months ended September 30, 2026 and 2025 were as follows (in millions):
*On May 1, 2025, we disposed of our IV Solutions business which was included within our Vital Care product line. The nine months ended September 30, 2025 includes $127.4 million of revenue, including contract manufacturing revenue, primarily related to the IV Solutions disposed business. Additionally, Vital Care includes contract manufacturing revenue, related primarily to our joint venture, of $4.2 million and $12.5 million for the three and nine months ended September 30, 2026, respectively, as compared to $3.6 million and $7.1 million of contract manufacturing revenue for the three and nine months ended September 30, 2025, respectively.
** Totals may differ from the income statement due to the rounding of product lines.
The Company Reaffirms Fiscal Year 2026 Guidance, Expecting Results at the High End of Range
The Company is reaffirming its full year 2026 guidance but expects to end the fiscal year towards the higher end of the guidance range. The Company's previously provided full year GAAP net income remains estimated to be in the range of $73 million to $83 million and GAAP diluted earnings per share to be in the range of $2.89 to $3.29. The Company's previously provided full year 2026 guidance of Adjusted EBITDA remains estimated to be in the range of $415 million to $435 million and adjusted diluted earnings per share to be in the range of $8.60 to $9.00.
The Company will host a conference call to discuss its third quarter financial results, today at 4:30 p.m. ET (1:30 p.m. PT). The call can be accessed at (800) 245-3047, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's website at www.icumed.com, clicking on the Investors tab, clicking on Event Calendar and clicking on the Webcast icon and following the prompts. The webcast will also be available by replay.
ICU Medical (Nasdaq: ICUI) is a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings. Our team is focused on providing quality, innovation and value to our clinical customers worldwide. ICU Medical is headquartered in San Clemente, California. More information about ICU Medical can be found at www.icumed.com .
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as
“aim,” “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” or the negative thereof or comparable terminology and may include (without limitation) information regarding the Company's expectations, goals and intentions regarding the future and financial outlook for 2026. These forward-looking statements are based on management's current expectations, estimates, forecasts and projections about the Company and assumptions management believes are reasonable, all of which are subject to risks and uncertainties that could cause actual results and events to differ materially from those stated in the forward-looking statements. These risks and uncertainties include, but are not limited to: risks from doing business in foreign countries, including related to tariffs and other barriers to trade; the Company’s ability to compete successfully, including with larger international companies and established local companies; decreased demand for the Company's products; costs related to product development; cost volatility or potential loss of supply of raw materials due to our dependence on single and limited source third-party suppliers; ability to achieve operating efficiencies; risks related to significant sales through our distributors; inflation and foreign currency exchange rates; impacts from global macroeconomic and geopolitical conditions, including from escalated conflicts in the Middle East and associated disruptions to shipping and increased oil costs; healthcare costs and reimbursement levels; disruptions at the FDA and other governmental agencies; damage at the Company’s manufacturing or supply facilities; risks associated with the IV Solutions joint venture and the Smiths Medical integration; risks associated with the timing and resolution of the 2025 warning letter; risks related to protection of our information technology systems and compliance with privacy laws and regulations; risks related to our intellectual property; and the other important factors described under “Risk Factors” in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and our subsequent filings with the SEC. Forward-looking statements contained in this press release are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise unless required by law.
September 30, December 31, 2026 2025 ────────────────────────────────────────────────────────────────────────────── ASSETS CURRENT ASSETS: Cash and cash $ 301,780 $ 307,963 equivalents Accounts receivable, net of allowance 206,258 180,515 for doubtful accounts Inventories 607,268 615,859 Prepaid expenses and other current 104,559 86,217 assets TOTAL CURRENT 1,219,865 1,190,554 ASSETS PROPERTY, PLANT AND EQUIPMENT, 444,991 451,817 net OPERATING LEASE RIGHT-OF-USE 36,170 54,470 ASSETS GOODWILL 1,482,783 1,499,754 INTANGIBLE 536,466 633,559 ASSETS, net DEFERRED INCOME 25,437 25,891 TAXES OTHER ASSETS 69,161 62,877 INVESTMENTS IN UNCONSOLIDATED 128,929 131,586 AFFILIATES TOTAL ASSETS $ 3,943,802 $ 4,050,508 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES: Accounts payable $ 142,989 $ 154,374 Accrued 342,805 315,337 liabilities Current portion 18,750 18,750 of long-term debt Income tax 10,089 10,400 payable TOTAL CURRENT 514,633 498,861 LIABILITIES LONG-TERM DEBT 1,133,096 1,265,917 OTHER LONG-TERM 68,969 89,536 LIABILITIES DEFERRED INCOME 8,764 37,756 TAXES INCOME TAX 26,922 34,613 LIABILITY COMMITMENTS AND CONTINGENCIES STOCKHOLDERS’ EQUITY: Convertible preferred stock, $1.00 par value; Authorized — — — 500 shares; Issued and outstanding — none Common stock, $0.10 par value; Authorized — 80,000 shares; Issued —25,186 and 24,688 shares at September 30, 2026 and December 31, 2,519 2,469 2025, respectively, and outstanding — 25,010 and 24,688 shares at September 30, 2026 and December 31, 2025, respectively Additional 1,487,156 1,465,118 paid-in capital Treasury stock, -23,040 -22 at cost Retained earnings 766,956 690,890 Accumulated other comprehensive -42,173 -34,630 loss TOTAL STOCKHOLDERS' 2,191,418 2,123,825 EQUITY TOTAL LIABILITIES AND STOCKHOLDERS' $ 3,943,802 $ 4,050,508 EQUITY
Nine months ended CASH FLOWS FROM OPERATING September 30, ACTIVITIES: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 76,066 $ 16,466 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 149,234 149,912 amortization Noncash lease expense 11,341 13,739 Stock compensation 37,744 41,879 Loss on disposal and write-off of property, plant and 2,074 3,211 equipment and other assets Debt issuance costs 2,398 5,112 amortization Undistributed equity in earnings of -266 -1,296 unconsolidated affiliates Net gain on sale of -2,240 -44,792 business Other 20,473 18,217 Changes in operating assets and liabilities, net of amounts acquired:
Accounts receivable -29,548 3,943 Inventories 2,319 -36,213 Prepaid expenses and other current -8,711 -4,721 assets Other assets -1,737 -7,149 Accounts payable -10,685 23,328 Accrued liabilities 12,770 -28,887 Income taxes, including excess tax -42,587 -33,501 benefits and deferred income taxes Net cash provided by operating 218,645 119,248 activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of property, plant and -45,999 -63,397 equipment Proceeds from sale of 5,931 211,185 business Proceeds from sale of 39 42 assets Intangible asset additions -5,245 -7,210 Net cash (used in) provided by investing -45,274 140,620 activities CASH FLOWS FROM FINANCING ACTIVITIES: Principal repayments of -134,688 -272,750 long-term debt Proceeds from exercise of 490 5,972 stock options Payments on finance leases -1,966 -1,543 Tax withholding payments related to net -39,166 -8,719 share settlement of equity awards Net cash used in financing -175,330 -277,040 activities Effect of exchange rate -4,224 8,338 changes on cash NET DECREASE IN CASH AND CASH -6,183 -8,834 EQUIVALENTS CASH AND CASH EQUIVALENTS, beginning of 307,963 308,566 period CASH AND CASH EQUIVALENTS, $ 301,780 $ 299,732 end of period
This press release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). The non- GAAP financial measures should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. There are material limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may not be comparable to similarly titled non-GAAP financial measures used by other companies, including peer companies. Our management believes that the non-GAAP data provides useful supplemental information to management and investors regarding our performance and facilitates a more meaningful comparison of results of operations between current and prior periods. We use non-GAAP financial measures in addition to and in conjunction with GAAP financial measures to analyze and assess the overall performance of our business, in making financial, operating and planning decisions, and in determining executive incentive compensation.
The non-GAAP financial measures as shown in the tables below, exclude special items because they are highly variable or unusual and impact year-over-year comparisons.
For the three months ended September 30, 2026 and 2025, special items include the following:
Contract manufacturing : We manufacture certain products or product components in accordance with manufacturing services agreements. We do not include the contract revenue in our adjusted revenue, or any gross profit impact in our adjusted gross profit as the commercial relationship under these types of agreements are originally negotiated contemporaneously with a business combination or other transactions and are not indicative of normal market transactions.
Stock compensation expense : Stock-based compensation is generally fixed at the time the stock-based instrument is granted and amortized over a period of several years. The value of our restricted stock awards is determined using the grant date stock price, which may not be indicative of our operational performance over the expense period. Additionally, in order to establish the fair value of performance-based stock awards, which are currently an element of our ongoing stock-based compensation, we are required to apply judgment to estimate the probability of the extent to which performance objectives will be achieved. Based on the above factors, we believe it is useful to exclude stock- based compensation in order to better understand our operating performance.
Intangible asset amortization expense : We do not acquire businesses or capitalize certain patent costs on a predictable cycle. The amount of purchase price allocated to intangible assets and the term of amortization can vary significantly and are unique to each acquisition. Capitalized patent costs can vary significantly based on our current level of development activities. We believe that excluding amortization of intangible assets provides the users of our financial statements with a consistent basis for comparison across accounting periods.
Restructuring, strategic transaction and integration : We incur restructuring and strategic transaction charges that result from events, which arise from unforeseen circumstances and/or often occur outside of the ordinary course of our ongoing business. Although these events are reflected in our GAAP financial statements, these unique transactions may limit the comparability of our ongoing operations with prior and future periods.
Settlements : Occasionally, we are involved in contract renegotiations or other events that may result in one-time settlements. We exclude these settlements as they have no direct correlation to the operation of our ongoing business.
Quality system and product-related remediation : We exclude certain quality system and product-related remediation charges in determining our non-GAAP financial measures as they may limit the comparability of our ongoing operations with prior and future periods and distort the evaluation of our normal operating performance.
Noncash release of loss on contract provision : We provide certain services under fixed priced arrangements in accordance with a transition services arrangement. We do not include the loss on contract provision or subsequent release net of the related interest accretion as a result of providing those services in our non-GAAP financial measures as the agreement was negotiated contemporaneously with a disposition and is not indicative of a normal market transaction. The loss provision and subsequent release is a non-recurring noncash adjustment that if included may limit the comparability of our ongoing operations with prior and future periods.
Gain on sale of business : We exclude any non-cash gains/losses on the sale of a business in determining our non-GAAP financial measures as the inclusion may limit the comparability of our ongoing operations with prior and future periods and distort the evaluation of our normal operating performance.
Impairment of equity method investment: We exclude impairment losses on equity method investments in determining our non-GAAP financial measures as they do not reflect the core, recurring operational performance of the business and may limit the
comparability of our ongoing operations with prior and future periods and distort the evaluation of our normal operating performance.
Tariff Refunds : We exclude certain IEEPA tariff refunds in determining our non- GAAP financial measures because these regulatory adjustments are infrequent, non-operational items that may limit the comparability of our ongoing operations with prior and future periods.
Noncash impairment and other JV items: We exclude our proportionate share of noncash impairment charges, accelerated depreciation, restructuring costs and other items recorded by our equity method investment joint ventures. We also exclude certain items that, based on our contractual relationship with our joint venture partner, are fully the responsibility of or for the benefit of our joint venture partner. We eliminate these items in determining our non-GAAP financial measures because they do not reflect the core, recurring operational performance of the underlying joint ventures and their inclusion would limit the comparability of our ongoing operations with prior and future periods and distort the evaluation of our normal operating performance.
From time to time in the future, there may be other items that we may exclude if we believe that doing so is not representative of our ordinary course operations and consistent with the goal of providing useful information to investors and management.
In addition to the above special items, Adjusted EBITDA additionally excludes the following items from net income:
Depreciation expense : We exclude depreciation expense in deriving adjusted EBITDA because companies utilize productive assets of different ages and the depreciable lives can vary significantly resulting in considerable variability in depreciation expense among companies.
Interest, net : We exclude interest in deriving adjusted EBITDA as interest can vary significantly among companies depending on a company's level of income generating instruments and/or level of debt.
Taxes : We exclude taxes in deriving adjusted EBITDA as taxes are deemed to be non-core to the business and may limit the comparability of our ongoing operations with prior and future periods and distort the evaluation of our normal operating performance.
Adjusted Diluted EPS excludes from diluted EPS, net of tax, the special items listed above. The tax effect on the special items is calculated using the specific tax rate applied to each adjustment based on the nature of the item/or the tax jurisdiction in which the item has been recorded. Additionally, adjusted diluted EPS may exclude the income tax impact of certain non-recurring discrete tax items that are not reflective of income tax expense/benefit incurred as a result of current period earnings/ loss, as well as the impact of certain deferred tax valuation allowances when assessed against non-GAAP profitability.
We also present Free cash flow as a non-GAAP financial measure as management believes that this is an important measure for use in evaluating overall company financial performance as it measures our ability to generate additional cash flow from business operations. Free cash flow should be considered in addition to, rather than as a substitute for, net income as a measure of our performance or net cash provided by operating activities as a measure of our liquidity. Additionally, our definition of free cash flow is limited and does not represent residual cash flows available for discretionary expenditures due to the fact that the measure does not deduct the payments required for debt service and other obligations or payments made for business acquisitions. Therefore, we believe it is important to view free cash flow as supplemental to our entire statement of cash flows.
We also present organic revenue growth as a non-GAAP financial measure as management believes that this measure provides a more representative view of the Company's underlying growth trajectory by excluding the impact of revenue from non-arm's length transactions, the impact of foreign currency and the revenue associated with acquisitions and divestitures. We calculate constant currency revenue by translating current period foreign currency revenue at prior period comparable exchange rates and we calculate the constant currency growth percentages by dividing the current period constant currency revenue by the prior year comparable period revenue.
The following tables reconcile our non-GAAP financial measures for the periods presented:
Adjusted EBITDA Three months ended September 30, 2026 2025 ────────────────────────────────────────────────────────────────────────────── GAAP net income (loss) $ 26,847 $ -3,396 Non-GAAP adjustments: Interest, net 15,240 19,808 Stock compensation 11,863 15,243 expense Depreciation and 49,594 50,802 amortization expense Restructuring, strategic transaction and 6,271 13,138 integration Settlements 1,130 1,426 Quality system and product-related 6,610 13,797 remediation Gain on sale of business -2,240 -2,969 Impairment of equity 2,832 — method investment Noncash release of loss on contract -1,120 -1,076 provision Gross profit on contract -719 -204 manufacturing Tariff refunds -10,358 — Noncash impairment and 766 — other JV items Provision for income 7,193 -658 taxes Total non-GAAP 87,062 109,307 adjustments Adjusted EBITDA $ 113,909 $ 105,911
(In thousands, except percentages and per share data) The Company’s U.S. GAAP results for the three months ended September 30, 2026 included special items which impacted the U.S. GAAP measures as follows:
* The Company’s non-GAAP annual effective tax rate is calculated without the tax expense related to the valuation allowance against certain U.S. Federal and State deferred tax assets, as well as, the tax benefit on the release of income tax reserves in foreign jurisdictions for tax years which are no longer subject to an assessment from the local taxing authorities. The valuation allowance was recorded based on an assessment of available positive and negative evidence, including, predominantly, an estimate that we will be in a three-year cumulative U.S. loss position on a GAAP basis as of September30, 2026. However, based on the same assessment, including, predominantly, our being, in a three-year cumulative U.S. income position on a non-GAAP basis, which excludes the impact of our non-GAAP adjustments, we concluded that recording a valuation allowance would not have been appropriate for non-GAAP reporting. As a result, the tax expense for the valuation allowance was added back to our calculation of non- GAAP annual effective tax rate. Tax reserves were released as a result of the expiration of statute of limitations which resulted in a discrete tax benefit for GAAP purposes. This tax benefit is excluded from our non-GAAP annual effective tax rate to the extent it is not related to on-going business operations.
(In thousands, except percentages and per share data) The Company’s U.S. GAAP results for the three months ended September 30, 2025 included special items which impacted the U.S. GAAP measures as follows:
* The Company’s non-GAAP annual effective tax rate is calculated without the tax expense related to the valuation allowance against certain U.S. Federal and State deferred tax assets. The valuation allowance was recorded based on an assessment of available positive and negative evidence, including, predominantly, an estimate that we will be in a three-year cumulative U.S. loss position on a GAAP basis as of September 30, 2025. However, based on the same assessment, including, predominantly, our being, in a three-year cumulative U.S. income position on a non-GAAP basis, which excludes the impact of our non-GAAP adjustments, we concluded that recording a valuation allowance would not have been appropriate for non-GAAP reporting. As a result, the tax expense for the valuation allowance was added back to our calculation of non-GAAP annual effective tax rate.
(1) We manufacture certain products or product components in accordance with manufacturing services agreements. We do not include the contract revenue in our adjusted
revenue as the commercial relationship under these types of agreements are originally negotiated contemporaneously with a business combination or other transactions and
(2) For businesses divested, non-GAAP organic revenue growth excludes prior period revenue associated with the divested business for the same length
of time they were not owned by the company in the current year. The divested business prior period revenue in this line item does not include MSA revenue, which is excluded on a separate line.
(3) We exclude the impact of foreign exchange rate changes to show a constant currency comparison of our underlying business performance.
Net Debt Net Leverage As of September 30, Ratio Calculation 2026 ────────────────────────────────────────────────────────────────────────────── Current portion $ 18,750 of long-term debt Long-Term Debt 1,133,096 Total GAAP 1,151,846 Long-Term Debt Add: Unamortized Debt Issuance 7,967 Costs/Discounts(… Less: Cash and -301,780 cash equivalents Net Debt $ 858,033 (Non-GAAP) (1)Represents unamortized debt issuance costs and original issue discounts deducted from the carrying value of long-term debt on the Condensed Consolidated Balance Sheets in accordance with U.S. GAAP. Management adds back these costs to present total contractual principal obligations outstanding when evaluating debt leverage. TTM Adjusted EBITDA As of September 30, 2026 GAAP net income $ 60,332 Non-GAAP adjustments: Interest, net 68,124 Stock compensation 51,623 expense Depreciation and amortization 200,065 expense Restructuring, strategic 64,826 transaction and integration Settlements 1,300 Quality system and 30,883 product-related remediation Asset write-offs and similar 887 charges Gain on sale of -2,240 business Impairment of equity method 2,832 investment Noncash release of loss on -4,436 contract provision Gross profit on contract -1,807 manufacturing Tariff refunds -29,246 Noncash impairment and 766 other JV items Provision for -23,104 income taxes Total non-GAAP 360,473 adjustments TTM Adjusted $ 420,805 EBITDA Net Leverage Ratio Net Debt $ 858,033 Divided by: TTM $ 420,805 Adjusted EBITDA Net Leverage 2.04 x Ratio
Low End of High End of Guidance Guidance ────────────────────────────────────────────────────────────────────────────── GAAP net income $ 73 $ 83 Non-GAAP adjustments: Interest, net 65 65 Stock compensation 50 50 expense Depreciation and amortization 203 203 expense Restructuring, strategic 52 52 transaction and integration Quality and regulatory 25 25 initiatives and remediation Noncash release of loss on -4 -4 contract provision Gross profit on contract -2 -2 manufacturing Tariff refunds -19 -19 Benefit for -28 -18 income taxes Total non-GAAP $ 342 $ 352 adjustments Adjusted EBITDA $ 415 $ 435 GAAP income per $ 2.89 $ 3.29 share Non-GAAP adjustments: Stock compensation 1.98 1.98 expense Amortization 5.28 5.28 expense Restructuring, strategic 2.06 2.06 transaction and integration Quality and regulatory 0.99 0.99 initiatives and remediation Noncash release of loss on -0.12 -0.12 contract provision Gross profit on contract -0.08 -0.08 manufacturing Tariff refunds -0.79 -0.79 Tax benefit from discrete reserve release and -1.33 -1.33 valuation allowance Estimated income tax impact from -2.28 -2.28 adjustments Adjusted earnings per $ 8.60 $ 9.00 share
Full text with the tables
Exhibit 99.1
ICU Medical Announces Third Quarter 2026 Results
and Reaffirms Fiscal Year 2026 Guidance, Expecting Results at the High End of
Range
SAN CLEMENTE, Calif., November 5, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc.
(Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative
medical products, today announced financial results for the quarterly period
ended September 30, 2026.
Third Quarter 2026 Results
Third quarter 2026 GAAP revenue was $560.4 million, as compared to $537.0
million in the same period in the prior year. GAAP gross profit for the third
quarter of 2026 was $234.8 million, as compared to $200.9 million in the same
period in the prior year. GAAP gross margin for the third quarter of 2026 was
42%, as compared to 37% in the same period in the prior year. GAAP net income
for the third quarter of 2026 was $26.8 million, or $1.07 per diluted share, as
compared to GAAP net loss of $(3.4) million, or $(0.14) per diluted share, for
the third quarter of 2025. Adjusted diluted earnings per share for the third
quarter of 2026 was $2.44 as compared to $2.03 for the third quarter of 2025.
Adjusted EBITDA was $113.9 million for the third quarter of 2026 as compared to
$105.9 million for the third quarter of 2025.
Adjusted EBITDA and adjusted diluted earnings per share are measures calculated
and presented on the basis of methodologies other than in accordance with GAAP.
Please refer to the Use of Non-GAAP Financial Information following the
financial statements herein for further discussion and reconciliations of these
measures to GAAP measures.
Vivek Jain, ICU Medical’s Chief Executive Officer, said, “Third quarter results
were ahead of our expectations for Infusion Systems and generally in line with
expectations for the remainder of the business."
Revenues by product line for the three and nine months ended September 30, 2026
and 2025 were as follows (in millions):
T… N…
m… m…
e… e…
S… S…
… 3… $ 3… $
… 2… 2… C… 2… 2… C…
──────────────────────────────────────────────────────────────────────────────
… $ 2… $ 2… $ 1… $ 86… $ 82… $ 41…
… 1… 1… 1… 56… 50… 53…
…
… 6… 7… -… 21… 35… -1…
…
… $ 5… $ 5… $ 2… $ 1,… $ 1,… $ -4…
*On May 1, 2025, we disposed of our IV Solutions business which was included
within our Vital Care product line. The nine months ended September 30, 2025
includes $127.4 million of revenue, including contract manufacturing revenue,
primarily related to the IV Solutions disposed business. Additionally, Vital
Care includes contract manufacturing revenue, related primarily to our joint
venture, of $4.2 million and $12.5 million for the three and nine months ended
September 30, 2026, respectively, as compared to $3.6 million and $7.1 million
of contract manufacturing revenue for the three and nine months ended September
30, 2025, respectively.
** Totals may differ from the income statement due to the rounding of product
lines.
The Company Reaffirms Fiscal Year 2026 Guidance, Expecting Results at the High
End of Range
The Company is reaffirming its full year 2026 guidance but expects to end the
fiscal year towards the higher end of the guidance range. The Company's
previously provided full year GAAP net income remains estimated to be in the
range of $73 million to $83 million and GAAP diluted earnings per share to be in
the range of $2.89 to $3.29. The Company's previously provided full year 2026
guidance of Adjusted EBITDA remains estimated to be in the range of $415 million
to $435 million and adjusted diluted earnings per share to be in the range of
$8.60 to $9.00.
Conference Call
The Company will host a conference call to discuss its third quarter financial
results, today at 4:30 p.m. ET (1:30 p.m. PT). The call can be accessed at (800)
245-3047, conference ID "ICUMED". The conference call will be simultaneously
available by webcast, which can be accessed by going to the Company's website at
www.icumed.com, clicking on the Investors tab, clicking on Event Calendar and
clicking on the Webcast icon and following the prompts. The webcast will also be
available by replay.
About ICU Medical
ICU Medical (Nasdaq: ICUI) is a global leader in infusion systems, infusion
consumables and high-value critical care products used in hospital, alternate
site and home care settings. Our team is focused on providing quality,
innovation and value to our clinical customers worldwide. ICU Medical is
headquartered in San Clemente, California. More information about ICU Medical
can be found at www.icumed.com .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Such statements contain words such
as
“aim,” “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,”
“expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,”
“potential,” “predict,” “project,” “should,” “target,” “will,” “would” or the
negative thereof or comparable terminology and may include (without limitation)
information regarding the Company's expectations, goals and intentions regarding
the future and financial outlook for 2026. These forward-looking statements are
based on management's current expectations, estimates, forecasts and projections
about the Company and assumptions management believes are reasonable, all of
which are subject to risks and uncertainties that could cause actual results and
events to differ materially from those stated in the forward-looking statements.
These risks and uncertainties include, but are not limited to: risks from doing
business in foreign countries, including related to tariffs and other barriers
to trade; the Company’s ability to compete successfully, including with larger
international companies and established local companies; decreased demand for
the Company's products; costs related to product development; cost volatility or
potential loss of supply of raw materials due to our dependence on single and
limited source third-party suppliers; ability to achieve operating efficiencies;
risks related to significant sales through our distributors; inflation and
foreign currency exchange rates; impacts from global macroeconomic and
geopolitical conditions, including from escalated conflicts in the Middle East
and associated disruptions to shipping and increased oil costs; healthcare costs
and reimbursement levels; disruptions at the FDA and other governmental
agencies; damage at the Company’s manufacturing or supply facilities; risks
associated with the IV Solutions joint venture and the Smiths Medical
integration; risks associated with the timing and resolution of the 2025 warning
letter; risks related to protection of our information technology systems and
compliance with privacy laws and regulations; risks related to our intellectual
property; and the other important factors described under “Risk Factors” in the
Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025
and our subsequent filings with the SEC. Forward-looking statements contained in
this press release are made only as of the date hereof, and the Company
undertakes no obligation to update or revise the forward-looking statements,
whether as a result of new information, future events or otherwise unless
required by law.
ICU MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
(In thousands)
September 30, December 31,
2026 2025
──────────────────────────────────────────────────────────────────────────────
ASSETS
CURRENT ASSETS:
Cash and cash $ 301,780 $ 307,963
equivalents
Accounts
receivable, net
of allowance 206,258 180,515
for doubtful
accounts
Inventories 607,268 615,859
Prepaid expenses
and other current 104,559 86,217
assets
TOTAL CURRENT 1,219,865 1,190,554
ASSETS
PROPERTY, PLANT
AND EQUIPMENT, 444,991 451,817
net
OPERATING LEASE
RIGHT-OF-USE 36,170 54,470
ASSETS
GOODWILL 1,482,783 1,499,754
INTANGIBLE 536,466 633,559
ASSETS, net
DEFERRED INCOME 25,437 25,891
TAXES
OTHER ASSETS 69,161 62,877
INVESTMENTS IN
UNCONSOLIDATED 128,929 131,586
AFFILIATES
TOTAL ASSETS $ 3,943,802 $ 4,050,508
LIABILITIES AND
STOCKHOLDERS’
EQUITY
CURRENT
LIABILITIES:
Accounts payable $ 142,989 $ 154,374
Accrued 342,805 315,337
liabilities
Current portion 18,750 18,750
of long-term debt
Income tax 10,089 10,400
payable
TOTAL CURRENT 514,633 498,861
LIABILITIES
LONG-TERM DEBT 1,133,096 1,265,917
OTHER LONG-TERM 68,969 89,536
LIABILITIES
DEFERRED INCOME 8,764 37,756
TAXES
INCOME TAX 26,922 34,613
LIABILITY
COMMITMENTS AND
CONTINGENCIES
STOCKHOLDERS’
EQUITY:
Convertible
preferred stock,
$1.00 par
value; Authorized — —
— 500 shares;
Issued
and outstanding —
none
Common stock,
$0.10 par value;
Authorized —
80,000 shares;
Issued
—25,186 and
24,688 shares at
September
30, 2026 and
December 31, 2,519 2,469
2025,
respectively, and
outstanding —
25,010
and 24,688 shares
at September 30,
2026
and December 31,
2025,
respectively
Additional 1,487,156 1,465,118
paid-in capital
Treasury stock, -23,040 -22
at cost
Retained earnings 766,956 690,890
Accumulated other
comprehensive -42,173 -34,630
loss
TOTAL
STOCKHOLDERS' 2,191,418 2,123,825
EQUITY
TOTAL LIABILITIES
AND STOCKHOLDERS' $ 3,943,802 $ 4,050,508
EQUITY
ICU MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
(In thousands, except per share data)
Three Nine
mont… months
ended ended
Sept… Septe…
30, 30,
2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
TOT… $ 560,… $ 536,… $ 1,64… $ 1,690…
REV…
COST
OF 325,… 336,… 966,… 1,071…
GOO…
SOLD
GRO… 234,… 200,… 676,… 619,0…
PRO…
OPE…
EXP…
Sel…
gen… 154,… 152,… 460,… 469,3…
and
adm…
Res…
and 21,7… 21,2… 65,7… 66,409
dev…
Res…
str…
tra… 6,271 13,1… 44,3… 46,053
and
int…
TOT…
OPE… 182,… 187,… 571,… 581,8…
EXP…
INC…
FROM 52,3… 13,7… 105,… 37,194
OPE…
INT…
EXP… -15,… -19,… -47,… -62,3…
net
OTH…
(EX… -3,1… 607 -4,4… 662
INC…
net
GAIN
ON
SALE 2,240 2,969 2,240 44,792
OF
BUS…
INC…
(LO…
BEF…
INC…
TAX…
AND
EQU… 36,1… -2,5… 55,3… 20,260
IN
(LO…
EAR…
OF
UNC…
AFF…
(PR…
BEN…
FOR -7,1… 658 20,4… -5,090
INC…
TAX…
NET
INC…
(LO… 28,9… -1,8… 75,8… 15,170
FROM
CON…
COM…
EQU…
IN
(LO…
EAR… -2,1… -1,5… 266 1,296
OF
UNC…
AFF…
NET
INC… $ 26,8… $ -3,3… $ 76,0… $ 16,466
(LO…
NET
INC…
(LO…
PER
SHA…
Bas… $ 1.07 $ -0.14 $ 3.05 $ 0.67
Dil… $ 1.07 $ -0.14 $ 3.02 $ 0.66
WEI…
AVE…
NUM…
OF
SHA…
Bas… 25,0… 24,6… 24,9… 24,624
Dil… 25,1… 24,6… 25,1… 24,783
ICU MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
(In thousands)
Nine months ended
CASH FLOWS FROM OPERATING September 30,
ACTIVITIES: 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net income $ 76,066 $ 16,466
Adjustments to reconcile
net income to
net cash provided by
operating
activities:
Depreciation and 149,234 149,912
amortization
Noncash lease expense 11,341 13,739
Stock compensation 37,744 41,879
Loss on disposal and
write-off of
property, plant and 2,074 3,211
equipment and other
assets
Debt issuance costs 2,398 5,112
amortization
Undistributed equity in
earnings of -266 -1,296
unconsolidated affiliates
Net gain on sale of -2,240 -44,792
business
Other 20,473 18,217
Changes in operating assets
and
liabilities, net of amounts
acquired:
Accounts receivable -29,548 3,943
Inventories 2,319 -36,213
Prepaid expenses and other
current -8,711 -4,721
assets
Other assets -1,737 -7,149
Accounts payable -10,685 23,328
Accrued liabilities 12,770 -28,887
Income taxes, including
excess tax -42,587 -33,501
benefits and deferred
income taxes
Net cash provided by
operating 218,645 119,248
activities
CASH FLOWS FROM INVESTING
ACTIVITIES:
Purchases of property,
plant and -45,999 -63,397
equipment
Proceeds from sale of 5,931 211,185
business
Proceeds from sale of 39 42
assets
Intangible asset additions -5,245 -7,210
Net cash (used in) provided
by investing -45,274 140,620
activities
CASH FLOWS FROM FINANCING
ACTIVITIES:
Principal repayments of -134,688 -272,750
long-term debt
Proceeds from exercise of 490 5,972
stock options
Payments on finance leases -1,966 -1,543
Tax withholding payments
related to net -39,166 -8,719
share settlement of equity
awards
Net cash used in financing -175,330 -277,040
activities
Effect of exchange rate -4,224 8,338
changes on cash
NET DECREASE IN CASH AND
CASH -6,183 -8,834
EQUIVALENTS
CASH AND CASH EQUIVALENTS,
beginning of 307,963 308,566
period
CASH AND CASH EQUIVALENTS, $ 301,780 $ 299,732
end of period
Use of Non-GAAP Financial Information
This press release contains financial measures that are not calculated in
accordance with U.S. generally accepted accounting principles ("GAAP"). The non-
GAAP financial measures should be considered supplemental to, and not as a
substitute for, or superior to, financial measures calculated in accordance with
GAAP. There are material limitations in using these non-GAAP financial measures
because they are not prepared in accordance with GAAP and may not be comparable
to similarly titled non-GAAP financial measures used by other companies,
including peer companies. Our management believes that the non-GAAP data
provides useful supplemental information to management and investors regarding
our performance and facilitates a more meaningful comparison of results of
operations between current and prior periods. We use non-GAAP financial measures
in addition to and in conjunction with GAAP financial measures to analyze and
assess the overall performance of our business, in making financial, operating
and planning decisions, and in determining executive incentive compensation.
The non-GAAP financial measures as shown in the tables below, exclude special
items because they are highly variable or unusual and impact year-over-year
comparisons.
For the three months ended September 30, 2026 and 2025, special items include
the following:
Contract manufacturing : We manufacture certain products or product components
in accordance with manufacturing services agreements. We do not include the
contract revenue in our adjusted revenue, or any gross profit impact in our
adjusted gross profit as the commercial relationship under these types of
agreements are originally negotiated contemporaneously with a business
combination or other transactions and are not indicative of normal market
transactions.
Stock compensation expense : Stock-based compensation is generally fixed at the
time the stock-based instrument is granted and amortized over a period of
several years. The value of our restricted stock awards is determined using the
grant date stock price, which may not be indicative of our operational
performance over the expense period. Additionally, in order to establish the
fair value of performance-based stock awards, which are currently an element of
our ongoing stock-based compensation, we are required to apply judgment to
estimate the probability of the extent to which performance objectives will be
achieved. Based on the above factors, we believe it is useful to exclude stock-
based compensation in order to better understand our operating performance.
Intangible asset amortization expense : We do not acquire businesses or
capitalize certain patent costs on a predictable cycle. The amount of purchase
price allocated to intangible assets and the term of amortization can vary
significantly and are unique to each acquisition. Capitalized patent costs can
vary significantly based on our current level of development activities. We
believe that excluding amortization of intangible assets provides the users of
our financial statements with a consistent basis for comparison across
accounting periods.
Restructuring, strategic transaction and integration : We incur restructuring
and strategic transaction charges that result from events, which arise from
unforeseen circumstances and/or often occur outside of the ordinary course of
our ongoing business. Although these events are reflected in our GAAP financial
statements, these unique transactions may limit the comparability of our ongoing
operations with prior and future periods.
Settlements : Occasionally, we are involved in contract renegotiations or other
events that may result in one-time settlements. We exclude these settlements as
they have no direct correlation to the operation of our ongoing business.
Quality system and product-related remediation : We exclude certain quality
system and product-related remediation charges in determining our non-GAAP
financial measures as they may limit the comparability of our ongoing operations
with prior and future periods and distort the evaluation of our normal operating
performance.
Noncash release of loss on contract provision : We provide certain services
under fixed priced arrangements in accordance with a transition services
arrangement. We do not include the loss on contract provision or subsequent
release net of the related interest accretion as a result of providing those
services in our non-GAAP financial measures as the agreement was negotiated
contemporaneously with a disposition and is not indicative of a normal market
transaction. The loss provision and subsequent release is a non-recurring
noncash adjustment that if included may limit the comparability of our ongoing
operations with prior and future periods.
Gain on sale of business : We exclude any non-cash gains/losses on the sale of a
business in determining our non-GAAP financial measures as the inclusion may
limit the comparability of our ongoing operations with prior and future periods
and distort the evaluation of our normal operating performance.
Impairment of equity method investment: We exclude impairment losses on equity
method investments in determining our non-GAAP financial measures as they do not
reflect the core, recurring operational performance of the business and may
limit the
comparability of our ongoing operations with prior and future periods and
distort the evaluation of our normal operating performance.
Tariff Refunds : We exclude certain IEEPA tariff refunds in determining our non-
GAAP financial measures because these regulatory adjustments are infrequent,
non-operational items that may limit the comparability of our ongoing operations
with prior and future periods.
Noncash impairment and other JV items: We exclude our proportionate share of
noncash impairment charges, accelerated depreciation, restructuring costs and
other items recorded by our equity method investment joint ventures. We also
exclude certain items that, based on our contractual relationship with our joint
venture partner, are fully the responsibility of or for the benefit of our joint
venture partner. We eliminate these items in determining our non-GAAP financial
measures because they do not reflect the core, recurring operational performance
of the underlying joint ventures and their inclusion would limit the
comparability of our ongoing operations with prior and future periods and
distort the evaluation of our normal operating performance.
From time to time in the future, there may be other items that we may exclude if
we believe that doing so is not representative of our ordinary course operations
and consistent with the goal of providing useful information to investors and
management.
In addition to the above special items, Adjusted EBITDA additionally excludes
the following items from net income:
Depreciation expense : We exclude depreciation expense in deriving adjusted
EBITDA because companies utilize productive assets of different ages and the
depreciable lives can vary significantly resulting in considerable variability
in depreciation expense among companies.
Interest, net : We exclude interest in deriving adjusted EBITDA as interest can
vary significantly among companies depending on a company's level of income
generating instruments and/or level of debt.
Taxes : We exclude taxes in deriving adjusted EBITDA as taxes are deemed to be
non-core to the business and may limit the comparability of our ongoing
operations with prior and future periods and distort the evaluation of our
normal operating performance.
Adjusted Diluted EPS excludes from diluted EPS, net of tax, the special items
listed above. The tax effect on the special items is calculated using the
specific tax rate applied to each adjustment based on the nature of the item/or
the tax jurisdiction in which the item has been recorded. Additionally, adjusted
diluted EPS may exclude the income tax impact of certain non-recurring discrete
tax items that are not reflective of income tax expense/benefit incurred as a
result of current period earnings/ loss, as well as the impact of certain
deferred tax valuation allowances when assessed against non-GAAP profitability.
We also present Free cash flow as a non-GAAP financial measure as management
believes that this is an important measure for use in evaluating overall company
financial performance as it measures our ability to generate additional cash
flow from business operations. Free cash flow should be considered in addition
to, rather than as a substitute for, net income as a measure of our performance
or net cash provided by operating activities as a measure of our liquidity.
Additionally, our definition of free cash flow is limited and does not represent
residual cash flows available for discretionary expenditures due to the fact
that the measure does not deduct the payments required for debt service and
other obligations or payments made for business acquisitions. Therefore, we
believe it is important to view free cash flow as supplemental to our entire
statement of cash flows.
We also present organic revenue growth as a non-GAAP financial measure as
management believes that this measure provides a more representative view of the
Company's underlying growth trajectory by excluding the impact of revenue from
non-arm's length transactions, the impact of foreign currency and the revenue
associated with acquisitions and divestitures. We calculate constant currency
revenue by translating current period foreign currency revenue at prior period
comparable exchange rates and we calculate the constant currency growth
percentages by dividing the current period constant currency revenue by the
prior year comparable period revenue.
The following tables reconcile our non-GAAP financial measures for the periods
presented:
ICU MEDICAL, INC. AND SUBSIDIARIES
Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)
(In thousands)
Adjusted EBITDA
Three months ended
September 30,
2026 2025
──────────────────────────────────────────────────────────────────────────────
GAAP net income (loss) $ 26,847 $ -3,396
Non-GAAP adjustments:
Interest, net 15,240 19,808
Stock compensation 11,863 15,243
expense
Depreciation and 49,594 50,802
amortization expense
Restructuring, strategic
transaction and 6,271 13,138
integration
Settlements 1,130 1,426
Quality system and
product-related 6,610 13,797
remediation
Gain on sale of business -2,240 -2,969
Impairment of equity 2,832 —
method investment
Noncash release of loss
on contract -1,120 -1,076
provision
Gross profit on contract -719 -204
manufacturing
Tariff refunds -10,358 —
Noncash impairment and 766 —
other JV items
Provision for income 7,193 -658
taxes
Total non-GAAP 87,062 109,307
adjustments
Adjusted EBITDA $ 113,909 $ 105,911
ICU MEDICAL, INC. AND SUBSIDIARIES
Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)
(In thousands, except percentages and per share data)
The Company’s U.S. GAAP results for the three months ended September 30, 2026
included special items which impacted the U.S. GAAP measures as follows:
──────────────────────────────────────────────────────────────────────────────
______________________
* The Company’s non-GAAP annual effective tax rate is calculated without the tax
expense related to the valuation allowance against certain U.S. Federal and
State deferred tax assets, as well as, the tax benefit on the release of income
tax reserves in foreign jurisdictions for tax years which are no longer subject
to an assessment from the local taxing authorities. The valuation allowance was
recorded based on an assessment of available positive and negative evidence,
including, predominantly, an estimate that we will be in a three-year cumulative
U.S. loss position on a GAAP basis as of September30, 2026. However, based on
the same assessment, including, predominantly, our being, in a three-year
cumulative U.S. income position on a non-GAAP basis, which excludes the impact
of our non-GAAP adjustments, we concluded that recording a valuation allowance
would not have been appropriate for non-GAAP reporting. As a result, the tax
expense for the valuation allowance was added back to our calculation of non-
GAAP annual effective tax rate. Tax reserves were released as a result of the
expiration of statute of limitations which resulted in a discrete tax benefit
for GAAP purposes. This tax benefit is excluded from our non-GAAP annual
effective tax rate to the extent it is not related to on-going business
operations.
** Amounts may not foot due to rounding.
ICU MEDICAL, INC. AND SUBSIDIARIES
Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)(continued)
(In thousands, except percentages and per share data)
The Company’s U.S. GAAP results for the three months ended September 30, 2025
included special items which impacted the U.S. GAAP measures as follows:
──────────────────────────────────────────────────────────────────────────────
_____________
* The Company’s non-GAAP annual effective tax rate is calculated without the tax
expense related to the valuation allowance against certain U.S. Federal and
State deferred tax assets. The valuation allowance was recorded based on an
assessment of available positive and negative evidence, including,
predominantly, an estimate that we will be in a three-year cumulative U.S. loss
position on a GAAP basis as of September 30, 2025. However, based on the same
assessment, including, predominantly, our being, in a three-year cumulative U.S.
income position on a non-GAAP basis, which excludes the impact of our non-GAAP
adjustments, we concluded that recording a valuation allowance would not have
been appropriate for non-GAAP reporting. As a result, the tax expense for the
valuation allowance was added back to our calculation of non-GAAP annual
effective tax rate.
** Amounts may not foot due to rounding
ICU MEDICAL, INC. AND SUBSIDIARIES
Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)(continued)
(In thousands, except percentages)
Rec…
of
GAAP
rev…
gro…
to Three Nine
Non… mont… mont…
org… ended ended
rev… Sept… Sept…
gro… 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Con…
GAAP $ 298,… $ 285,… $ 865,… $ 824,…
rev…
Con…
GAAP 5 % 8 % 5 % 7 %
rev…
gro…
For…
cur… -231 -8,9…
imp…
Non…
org… $ 298,… $ 285,… $ 856,… $ 824,…
rev…
Non…
org… 5 % 4 %
rev…
gro…
Inf…
Sys… $ 192,… $ 173,… $ 561,… $ 507,…
GAAP
rev…
Inf…
Sys…
GAAP 11 % 9 % 10 % 6 %
rev…
gro…
For…
cur… -54 -4,6…
imp…
Non…
org… $ 192,… $ 173,… $ 556,… $ 507,…
rev…
Non…
org… 11 % 10 %
rev…
gro…
Vit…
Care $ 69,5… $ 77,9… $ 215,… $ 358,…
GAAP
rev…
Vit…
Care
GAAP -11 % -53 % -40 % -28 %
rev…
gro…
MSA -4,2… -3,6… -12,… -14,…
Rev…
Non…
adj… 65,2… 74,2… 202,… 344,…
rev…
Non…
adj… -12 % -52 % -41 % -26 %
rev…
gro…
Les…
Rev…
from 332 -803 332 -120…
div…
bus…
For…
cur… 301 -1,0…
imp…
Non…
org… $ 65,9… $ 73,4… $ 202,… $ 223,…
rev…
Non…
org… -10 % -10 %
rev…
gro…
Tot…
GAAP $ 560,… $ 536,… $ 1,64… $ 1,69…
rev…
Tot…
GAAP 4 % -9 % -3 % -4 %
rev…
gro…
MSA -4,2… -3,6… -12,… -14,…
Rev…
Non…
adj… 556,… 533,… 1,62… 1,67…
rev…
Non…
adj… 4 % -8 % -3 % -2 %
rev…
gro…
Les…
Rev…
from 332 -803 332 -120…
div…
bus…
For…
cur… 16 -14,…
imp…
Non…
org… $ 556,… $ 532,… $ 1,61… $ 1,55…
rev…
Non…
org… 5 % 4 %
rev…
gro…
_____________________________________________
(1) We manufacture certain products or product components in accordance with
manufacturing services agreements. We do not include the contract revenue in our
adjusted
revenue as the commercial relationship under these types of agreements are
originally negotiated contemporaneously with a business combination or other
transactions and
are not indicative of normal market transactions.
(2) For businesses divested, non-GAAP organic revenue growth excludes prior
period revenue associated with the divested business for the same length
of time they were not owned by the company in the current year. The divested
business prior period revenue in this line item does not include MSA revenue,
which is excluded on a separate line.
(3) We exclude the impact of foreign exchange rate changes to show a constant
currency comparison of our underlying business performance.
ICU MEDICAL, INC. AND SUBSIDIARIES
Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)(continued)
(In thousands)
Reconc…
of Net
Cash
Provid…
by
Operat… Three Nine
Activi… months months
to Free ended ended
Cash Septem… Septemb…
Flow 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net
cash
provid… $ 99,586 56,710 $ 218,645 $ 119,248
by
operat…
activi…
Purcha…
of
proper… -16,186 -29,080 -45,999 -63,397
plant
and
equipm…
Procee…
from 17 — 39 42
sale of
assets
Free
cash $ 83,417 $ 27,630 $ 172,685 $ 55,893
flow
ICU MEDICAL, INC. AND SUBSIDIARIES
Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)(continued)
(In thousands)
Net Debt
Net Leverage As of September 30,
Ratio Calculation 2026
──────────────────────────────────────────────────────────────────────────────
Current portion $ 18,750
of long-term debt
Long-Term Debt 1,133,096
Total GAAP 1,151,846
Long-Term Debt
Add: Unamortized
Debt Issuance 7,967
Costs/Discounts(…
Less: Cash and -301,780
cash equivalents
Net Debt $ 858,033
(Non-GAAP)
(1)Represents
unamortized debt
issuance
costs and
original issue
discounts
deducted from the
carrying value of
long-term debt on
the Condensed
Consolidated
Balance Sheets in
accordance with
U.S. GAAP.
Management
adds back these
costs to present
total
contractual
principal
obligations
outstanding when
evaluating debt
leverage.
TTM Adjusted EBITDA
As of September 30,
2026
GAAP net income $ 60,332
Non-GAAP
adjustments:
Interest, net 68,124
Stock
compensation 51,623
expense
Depreciation and
amortization 200,065
expense
Restructuring,
strategic 64,826
transaction and
integration
Settlements 1,300
Quality system
and 30,883
product-related
remediation
Asset write-offs
and similar 887
charges
Gain on sale of -2,240
business
Impairment of
equity method 2,832
investment
Noncash release
of loss on -4,436
contract
provision
Gross profit on
contract -1,807
manufacturing
Tariff refunds -29,246
Noncash
impairment and 766
other JV items
Provision for -23,104
income taxes
Total non-GAAP 360,473
adjustments
TTM Adjusted $ 420,805
EBITDA
Net Leverage Ratio
Net Debt $ 858,033
Divided by: TTM $ 420,805
Adjusted EBITDA
Net Leverage 2.04 x
Ratio
ICU MEDICAL, INC. AND SUBSIDIARIES
Fiscal Year 2026
Outlook (Unaudited)
(In millions, except per share data)
Low End of High End of
Guidance Guidance
──────────────────────────────────────────────────────────────────────────────
GAAP net income $ 73 $ 83
Non-GAAP
adjustments:
Interest, net 65 65
Stock
compensation 50 50
expense
Depreciation and
amortization 203 203
expense
Restructuring,
strategic 52 52
transaction and
integration
Quality and
regulatory 25 25
initiatives and
remediation
Noncash release
of loss on -4 -4
contract
provision
Gross profit on
contract -2 -2
manufacturing
Tariff refunds -19 -19
Benefit for -28 -18
income taxes
Total non-GAAP $ 342 $ 352
adjustments
Adjusted EBITDA $ 415 $ 435
GAAP income per $ 2.89 $ 3.29
share
Non-GAAP
adjustments:
Stock
compensation 1.98 1.98
expense
Amortization 5.28 5.28
expense
Restructuring,
strategic 2.06 2.06
transaction and
integration
Quality and
regulatory 0.99 0.99
initiatives and
remediation
Noncash release
of loss on -0.12 -0.12
contract
provision
Gross profit on
contract -0.08 -0.08
manufacturing
Tariff refunds -0.79 -0.79
Tax benefit from
discrete reserve
release and -1.33 -1.33
valuation
allowance
Estimated income
tax impact from -2.28 -2.28
adjustments
Adjusted
earnings per $ 8.60 $ 9.00
share
CONTACT:
ICU Medical, Inc.
Brian Bonnell, Chief Financial Officer
(949) 366-2183
ICR, Inc.
John Mills, Partner
(646) 277-1254